ADDENTAX GROUP CORP. (ATXG): Nasdaq/NYSE listing notice — Addentax receives Nasdaq delisting notice for bid price below $1.00

ADDENTAX GROUP CORP.

Nasdaq notified Addentax on June 15, 2023 that its common stock bid price was below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until December 12, 2023) to regain compliance by closing at $1.00 for 10 consecutive business days.
If non-compliant by Dec. 12, may be eligible for an additional 180-day grace period subject to meeting other listing standards and curing deficiency.
Shares continue trading under symbol 'ATXG' on Nasdaq during the compliance period; delisting is not immediate.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

ADDENTAX GROUP CORP. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 15, 2023, from the Listings Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share of its common stock was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Nasdaq notification letter does not result in the immediate delisting of the Company’s common stock, and the shares will continue to trade uninterrupted under the symbol “ATXG.” Pursuant to Nasdaq

View on SEC.gov

Browse all listing & compliance notices →

ADDENTAX GROUP CORP. filing history →

Source: SEC EDGAR

accession 0001493152-23-021738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.